Mar 19, 2020
Hansoh Pharma's Ameile (Almonertinib) Receives Marketing Authorization in China for Second-Line Treatment for Patients With EGFR T790M-Mutation Non-Small Cell Lung Cancer
Dec 19, 2019
Bridge Biotherapeutics Files Investigational New Drug Application for BBT-176, an EGFR TKI for NSCLC
Sep 10, 2019
Updated Phase 1 Data for Daiichi Sankyo's U3-1402 in Patients with EGFR Mutated NSCLC Presented at 2019 World Conference on Lung Cancer
Aug 05, 2019
Updated real-world data show Gilotrif® followed by osimertinib provided a median overall survival of up to almost four years in patients with EGFR Del19 and T790M mutation-positive NSCLC
Jul 01, 2019
The global EGFR inhibitors market at a CAGR of almost 9% during the forecast period
May 30, 2019
Sysmex Inostics OncoBEAM(TM)-EGFR Digital PCR Liquid Biopsy Demonstrates Two-fold Higher Detection of p.T790M Mutations in 183 NSCLC Patients in Comparison Study
May 29, 2019
Sihuan Pharm Obtained Phase I to III Clinical Trial Approval for the Third Generation of EGFR Inhibitor XZP-5809
May 28, 2019
Bio-Techne's New Exosome-Based Liquid Biopsies Helping To Advance Personalized Care In Lung Cancer Diagnostics
Mar 21, 2019
Kanazawa University Research: Origin of Resistance to Lung-cancer Drug Discovered
Nov 15, 2018
Patients Launch New Study to Shed Light on EGFR-Positive Lung Cancers
Oct 18, 2018
Daiichi Sankyo Initiates Phase 1 Study of AXL Inhibitor DS-1205 in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer
Oct 18, 2018
Sysmex Inostics' OncoBEAM(TM) Platform Demonstrates Superior Detection of Clinically-relevant Mutations for Therapy Selection and Molecular Monitoring for Lung and Colon Cancers
Sep 26, 2018
Blueprint Medicines Announces Proof-of-Concept Data Showing Combination of BLU-667 and Osimertinib Overcame Treatment Resistance in Two Patients with EGFR-Mutant, Non-Small Cell Lung Cancer and an Acquired RET Fusion
Apr 18, 2018
Roche expands indication for cobas® EGFR Mutation Test v2 as a companion diagnostic with TAGRISSO®
Apr 18, 2018
US FDA Approves TAGRISSO® (osimertinib) As 1st-Line Treatment For EGFR-Mutated Non-Small Cell Lung Cancer
Feb 06, 2018
Daiichi Sankyo Initiates Phase 1 Study of U3-1402 in Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
Jan 09, 2018
BerGenBio Meets First Efficacy Endpoint in Phase II Trial With Selective AXL Inhibitor BGB324 (bemcentinib) in NSCLC
Dec 12, 2017
Boehringer Ingelheim initiates real-world study of treatment sequencing in EGFR mutation-positive lung cancer
Sep 26, 2017
OncoBEAM[TM] EGFR Kit (RUO) at Jessenius Medical Faculty of Comenius University and its University Hospital, in Martin, Slovakia